The Generic Semaglutide Era in India (2026): What Cheaper Ozempic Really Means

For years, semaglutide in India was a rich person’s drug. Ozempic and Wegovy cost more per month than a lot of families spend on groceries, and there was no cheaper legal option. Then, almost overnight in 2026, that changed.

On 20 March 2026, Novo Nordisk’s Indian patent on semaglutide expired. Within a day, Indian companies launched their own versions and a price war started. Those headlines you’ve seen about “Ozempic 90% cheaper”? This is what they’re about. Here’s what really changed, including the parts the headlines skip.

What happened, briefly

A patent is a temporary monopoly. While it holds, only the originator can sell the drug, so they set the price. Once it lapses, anyone approved can make the same molecule, and competition drags the price down. It’s the story of nearly every drug that has ever gone generic. It just happened to semaglutide, in India, in March 2026.

Two things followed. First, a wave of Indian generic brands arrived from Sun Pharma, Dr Reddy’s, Zydus, Alkem, Glenmark, Torrent, Eris and others. Second, Novo Nordisk cut its own prices to compete — Ozempic by around a third, and Wegovy’s starting dose by roughly half, from April 2026.

The real prices now

A grounded snapshot (monthly, MRP — street prices often run a little lower):

Option	Type	Approx. monthly cost
Sundae (Eris)	Generic semaglutide, vial	~₹1,290
GLIPIQ (Glenmark)	Generic semaglutide, vial	~₹1,300
Semasize (Alkem)	Generic semaglutide, pen	from ~₹1,800
Ozempic (Novo Nordisk)	Innovator, T2D	₹5,660–9,100
Wegovy (Novo Nordisk)	Innovator, obesity	₹5,660–16,400
Mounjaro (Eli Lilly)	Tirzepatide — different molecule, still patented	₹14,000–27,500

So yes, a vial-format generic can cost roughly a quarter of what innovator Ozempic does. For a therapy you might stay on for a year or more, that is life-changing money.

The catch nobody mentions: pen vs vial pricing

Not every “cheap generic” is as cheap as it sounds, and this is where people get caught. Some generics, especially prefilled pens, are advertised with a per-injection price rather than a monthly one. Semaglutide is a once-weekly shot, so you take four a month. A pen quoted at “₹900–2,000 a shot” therefore works out to roughly ₹3,600–8,000 a month — still under the innovator at the top end, but nowhere near the bargain the per-shot number implies.

The genuinely cheap options right now are the vial-format generics like Sundae and GLIPIQ, landing near ₹1,290–1,300 a month. Whenever you compare prices, ask the same question: is this per shot, or per month?

“Same molecule” — is a generic as good?

A generic semaglutide contains the identical active molecule as Ozempic and is approved by India’s drug regulator (DCGI/CDSCO) on the basis of bioequivalence — meaning it’s expected to behave the same in your body. What differs between brands is the packaging: vial or pen, needle design, how many dose strengths, cold-chain quality, manufacturer support. Those are real, practical differences. The medicine inside is the same.

What to be careful about

• It’s still prescription-only. Semaglutide is a Schedule H drug. Cheaper doesn’t mean over-the-counter — you still need a doctor’s prescription, and your health reviewed first.
• Counterfeits followed the hype. Fake semaglutide pens have circulated in India. Be wary of anything sold at a suspiciously deep discount or through informal channels; buy from licensed pharmacies against a real prescription.
• Cheapest isn’t automatically best for you. If self-injecting at home matters, a pen can be worth the extra over a vial meant for clinic use. Fit matters, not just the sticker price.
• Tirzepatide (Mounjaro) has not gone generic. It’s a different molecule, still under patent in India until roughly 2036, so there’s no cheap generic version — only the branded product, at branded prices.

The bottom line

The patent cliff genuinely changed the maths. Semaglutide therapy that once cost ₹8,000+ a month now starts near ₹1,290 for a vial generic — the same molecule, legally, from established Indian manufacturers. The smart move is to read the price in months, not shots, and to start with a doctor rather than a discount.

For the full brand-by-brand breakdown, see our India semaglutide brands page and the cost pages. And if you’re not sure whether you’re even a candidate, the free 5-minute check is the right first step — it’s built on Indian BMI cut-offs and will tell you honestly when GLP-1 isn’t the answer.

Prices reflect publicly reported MRP around mid-2026 and change over time; confirm current pricing with a licensed pharmacy. This article is general information, not medical or financial advice.